Corner is utilising its novel dendritic cell stimuli platforms to create therapeutic cancer and infectious disease vaccines that could provide life-long immunity.

In Q2 2024, the company announces $54 million in Series A funding, led by Ziff Capital Partners and including Cockrell Interests, Tanis Ventures, and Sandia Holdings. The company hopes to use the proceeds to initiate its first clinical study in 2025.